Human soluble p66 and p51 tumor-associated antigens promote the suppression of rat mammary tumors in comparison to commercial human albumin

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 487-491

  Kossoy, George ^a   Avinoach, Ilana ^b   Zusman, Itshak ^a   Scheider, David P ^c   Ben Hur, Herzl ^d   Elhayany, Asher ^e  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Dept of Internal Medicine C   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d Kiryat Weitzman   (Israel)

^e CLALIT HEALTH SERVICES   (Israel)

Author keywords

Dimethylbenzanthracene; Human albumin; Mammary tumors; Tumor associated antigens p66 and p51

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; SERUM ALBUMIN; TUMOR ANTIGEN;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR WEIGHT; PATHOLOGY; RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, NEOPLASM; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MOLECULAR WEIGHT; RATS; SERUM ALBUMIN;

EID: 3242743128     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.487     Document Type: Article

References (33)

1. DeMatos P and Seigler HF: Monitoring antitumor immune response during immunotherapy of cancer. Why and how? Biodrugs 11: 239-247, 1999. (Pubitemid 29189935)
2. Minev BR, Chavez FL and Mitchell MS: Cancer vaccines: novel approaches and new promise. Pharmacol Ther 81: 121-139, 1999. (Pubitemid 29073560)
3. Baultz JK: Vaccines in the treatment of cancer. Am J Health-Syst Pharm 52: 2574-2585, 1995.
4. Zöller M and Matzku S: Cancer therapy: New concepts on active immunization. Immunobiology 201: 1-21, 1999. (Pubitemid 29457297)
5. Ben-Hur H, Kossoy G, Sandler B and Zusman I: Vaccination with soluble low-molecular weight tumor-associated proteins suppresses chemically-induced mammary tumorigenesis in rats. In Vivo 14: 551-554, 2000. (Pubitemid 30618017)
6. Sandler B, Smirnoff P, Ben-Hur H, Zusman R and Zusman I: An improved method for isolation and purification of soluble tumor-associated proteins from the serum of cancer patients. Exp Oncol 21: 55-58, 1999.
7. Hersey P: Impediments to successful immunotherapy. Pharm Ther 81: 111-119, 1999.
8. Hipp JD, Hipp JA, Lyday BW and Minev BR: Cancer vaccines: An update. In Vivo 14: 571-585, 2000. (Pubitemid 34097518)
9. Knuth A, Jager D and Jager E: Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol 46: S46-S51, 2000.
10. Kuroki M, Ueno A, Matsumoto H, Abe H, Li T, Imakiire T, Yamauchi Y, Uno K, Shirota K, Shibaguchi H and Kuroki M: Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview. Anticancer Res 22: 4255-4264, 2002. (Pubitemid 36134469)
11. Tanaka Y, Amos KD, Fleming TP, Eberlein TJ and Goedegebuure PS: Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. Surgery 133: 74-80, 2003. (Pubitemid 36183129)
12. Neeley YC, McDonagh KT, Overwijk WW, Restifo NP and Sanda MG: Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate 53: 183-191, 2002. (Pubitemid 35266178)
13. Modak S, Gerald W and Cheung NK: Disialoganglioside GD2 and a novel: tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol 39: 547-551, 2002. (Pubitemid 35191435)
14. Gotte K, Usener D, Riedel F, Hormann K, Schadendorf D and Eichmuller S: Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes. Acta Otolaryngol 122: 546-552, 2002. (Pubitemid 34913438)
15. Pellat-Deceunynck C: Tumour-associated antigens in multiple myeloma. Br J Haematol 120: 3-9, 2003.
16. Zusman I, Zusman R, Korol D, Sandler B, Ben-Hur H, Bass D, Mashiah A, Lifschitz-Mercer B, Smirnoff P and Glick J: Isolation of p53 protein from the serum of colon cancer and non-cancer patients. Oncol Rep 2: 679-683, 1995.
17. Ben-Hur H, Plonsky E, Gurevich P, Berman V, Moriel E, Guy M, Sandler B, Rozenberg V and Zusman I: Immune response of the rat splenic lymphoid system to tumor-suppressor effects of liposomes-bearing soluble p53 antigen on chemically-induced rat colon cancer: A morphometric study. Int J Mol Med 3: 545-549, 1999.
18. Ben-Hur H, Kossoy G, Sandler B, Zusman I: Vaccination with soluble low-molecular weight tumor-associated proteins suppresses chemically-induced mammary tumorigenesis in rats. In Vivo 14: 551-554, 2000. (Pubitemid 30618017)
19. Bunikis J and Barbour AG: Access of antibody or trypsin to an integral outer membrane protein (P66) of Borrelia burgdorferi is hindered by Osp lipoproteins. Infect Immun 67: 2874-2883, 1999. (Pubitemid 29244703)
20. Matsumoto S, Ogawa M, Kasakura T, Shimada Y, Mitsui M Maruya M, Isohata M, Yahara I and Murakami-Murofushi K: A novel 66-kDa stress protein, p66, associated with the process of cyst formation of Physarum polycephalum is a Physarum homologue of a yeast actin-interacting protein, AIP1. J Biochem 124: 326-331, 1998. (Pubitemid 28419677)
21. Tvorogov DB, Blagoveshchenskaia AD, Tsupkina NV and Medvedeva ND: The characteristics of protein p66 - a substrate of the epidermal growth factor receptor. Tsitologiia 39: 835-841, 1997.
22. Martins VR and Brentani RR: The biology of the cellular prion protein. Neurochem Int 41: 353-355, 2002.
23. Shikata K, Ohta S, Yamada K, Obuse C, Yoshikawa H and Tsurimoto T: The human homologue of fission Yeast cdc27, p66, is a component of active human DNA polymerase delta. J Biochem 129: 699-708, 2001. (Pubitemid 32499781)
24. Stevenson LE and Frackelton AR Jr: Constitutively tyrosine phosphorylated p52 She in breast cancer cells: correlation with ErbB2 and p66 She expression. Breast Cancer Res Treat 49: 119-128, 1998. (Pubitemid 28279589)
25. Jackson JG, Yoneda T, Clark GM and Yee D: Elevated levels of p66 She are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res 6: 1135-1139, 2000. (Pubitemid 30159377)
26. Ikawa S, Obinata M and Ikawa Y: Human p53-p51 (p53-related) fusion protein: a potent BAX transactivator. Jpn J Cancer Res 90: 596-599, 1999. (Pubitemid 29332916)
27. Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K, Obinata M, Kanamaru R, Ikawa S and Ishioka C: The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 59: 2781-2786, 1999. (Pubitemid 29283107)
28. Sasaki Y, Morimoto I, Ishida S, Yamashita T, Imai K and Tokino T: Adenovims-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer. Gene Ther 8: 1401-1408, 2001. (Pubitemid 32895671)
29. Takahashi H, Fukutome K, Watanabe M, Furusato M, Shiraishi T, Ito H, Suzuki H, Ikawa S and Hano H: Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma. Prostate 47: 85-90, 2001. (Pubitemid 32336577)
30. Yamaguchi K, Patturajan M, Trink B, Usadel H, Koch W, Jen J and Sidransky D: Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients. Int J Cancer 89: 524-528, 2000.
31. + transporting ATP synthase on the surface of tumor cell lines. J Exp Med 180: 273-281, 1994.
32. Zusman I and Ben-Hur H: Serological markers for detection of cancer (Review). Int J Mol Med 7: 547-556, 2001.
33. Ginzburg M, Vol A, Smirnoff P, Sandler B and Zusman I: Autoimmunotherapy of type II diabetes with soluble low-molecular-mass antigens: a case report. In Vivo 16: 71-72, 2002. (Pubitemid 34436179)